Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Abstract Background Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles. We used a discrete choice experimen...

Full description

Bibliographic Details
Main Authors: Sandy Srinivas, Ateesha F. Mohamed, Sreevalsa Appukkuttan, Marc Botteman, Xinyi Ng, Namita Joshi, Erica Horodniceanu, A. Reginald Waldeck, Stacey J Simmons
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Urology
Subjects:
Prostatic neoplasms
Castration-resistant
Choice behavior
Risk assessment
Physicians
Online Access:http://link.springer.com/article/10.1186/s12894-020-00631-4

Internet

http://link.springer.com/article/10.1186/s12894-020-00631-4

Similar Items